LIVZON PHARMAC. GRP H YC1 (F:LP6) — Market Cap & Net Worth
Market Cap & Net Worth: LIVZON PHARMAC. GRP H YC1 (LP6)
LIVZON PHARMAC. GRP H YC1 (F:LP6) has a market capitalization of $757.09 Million (€647.58 Million) as of September 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #10259 globally and #1217 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LIVZON PHARMAC. GRP H YC1's stock price €2.16 by its total outstanding shares 299807117 (299.81 Million). Also see balance sheet size of LIVZON PHARMAC. GRP H YC1 for a full breakdown of the balance sheet.
LIVZON PHARMAC. GRP H YC1 Market Cap History: 2015 to 2026
LIVZON PHARMAC. GRP H YC1's market capitalization history from 2015 to 2026. Data shows growth from $3.96 Million to $757.09 Million (60.99% CAGR). Also see LIVZON PHARMAC. GRP H YC1 operating cash flow efficiency for how efficiently the company converts equity into cash flow.
LIVZON PHARMAC. GRP H YC1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LIVZON PHARMAC. GRP H YC1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check LP6 stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.09x
LIVZON PHARMAC. GRP H YC1's market cap is 0.09 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.54x
LIVZON PHARMAC. GRP H YC1's market cap is 0.54 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $114.72 Million | $12.06 Billion | $1.78 Billion | 0.01x | 0.06x |
| 2022 | $233.05 Million | $12.63 Billion | $1.91 Billion | 0.02x | 0.12x |
| 2023 | $462.35 Million | $12.43 Billion | $1.95 Billion | 0.04x | 0.24x |
| 2024 | $1.16 Billion | $11.81 Billion | $2.06 Billion | 0.10x | 0.56x |
| 2025 | $1.10 Billion | $12.02 Billion | $2.02 Billion | 0.09x | 0.54x |
Competitor Companies of LP6 by Market Capitalization
Companies near LIVZON PHARMAC. GRP H YC1 in the global market cap rankings as of September 19, 2026. Review LP6 tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to LIVZON PHARMAC. GRP H YC1 by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
LIVZON PHARMAC. GRP H YC1 Historical Marketcap From 2015 to 2026
Between 2015 and today, LIVZON PHARMAC. GRP H YC1's market cap moved from $3.96 Million to $ 757.09 Million, with a yearly change of 60.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €757.09 Million | -31.21% |
| 2025 | €1.10 Billion | -4.85% |
| 2024 | €1.16 Billion | +150.17% |
| 2023 | €462.35 Million | +98.39% |
| 2022 | €233.05 Million | +103.15% |
| 2021 | €114.72 Million | +64.72% |
| 2020 | €69.65 Million | +66.83% |
| 2019 | €41.75 Million | +160.61% |
| 2018 | €16.02 Million | +58.68% |
| 2017 | €10.09 Million | +71.43% |
| 2016 | €5.89 Million | +48.67% |
| 2015 | €3.96 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of LIVZON PHARMAC. GRP H YC1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $757.09 Million USD |
| MoneyControl | $757.09 Million USD |
| MarketWatch | $757.09 Million USD |
| marketcap.company | $757.09 Million USD |
| Reuters | $757.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About LIVZON PHARMAC. GRP H YC1
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, il… Read more